Search

Your search keyword '"Bosly, André"' showing total 149 results
Start Over Author "Bosly, André" Language english
149 results on '"Bosly, André"'

1. Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial

Author

Camus, Vincent, Belot, Aurélien, Oberic, Lucie, Sibon, David, Ghesquières, Hervé, Thieblemont, Catherine, Fruchart, Christophe, Casasnovas, Olivier, Michot, Jean-Marie, Molina, Thierry Jo, Bosly, André, Joubert, Clémentine, Haioun, Corinne, Nicolas-Virelizier, Emmanuelle, Feugier, Pierre, Fitoussi, Olivier, Delarue, Richard, and Tilly, Hervé

Published
2022
Full Text
View/download PDF

3. GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors

Author

Chiche, Johanna, Reverso-Meinietti, Julie, Mouchotte, Annabelle, Rubio-Patiño, Camila, Mhaidly, Rana, Villa, Elodie, Bossowski, Jozef P., Proics, Emma, Grima-Reyes, Manuel, Paquet, Agnès, Fragaki, Konstantina, Marchetti, Sandrine, Briere, Josette, Ambrosetti, Damien, Michiels, Jean-François, Molina, Thierry Jo, Copie-Bergman, Christiane, Lehmann-Che, Jacqueline, Peyrottes, Isabelle, Peyrade, Frederic, de Kerviler, Eric, Taillan, Bruno, Garnier, Georges, Verhoeyen, Els, Paquis-Flucklinger, Véronique, Shintu, Laetitia, Delwail, Vincent, Delpech-Debiais, Celine, Delarue, Richard, Bosly, André, Petrella, Tony, Brisou, Gabriel, Nadel, Bertrand, Barbry, Pascal, Mounier, Nicolas, Thieblemont, Catherine, and Ricci, Jean-Ehrland

Published
2019
Full Text
View/download PDF

4. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

Author

Hermine, Olivier, Hoster, Eva, Walewski, Jan, Bosly, André, Stilgenbauer, Stephan, Thieblemont, Catherine, Szymczyk, Michal, Bouabdallah, Reda, Kneba, Michael, Hallek, Michael, Salles, Gilles, Feugier, Pierre, Ribrag, Vincent, Birkmann, Josef, Forstpointner, Roswitha, Haioun, Corinne, Hänel, Mathias, Casasnovas, René Olivier, Finke, Jürgen, Peter, Norma, Bouabdallah, Kamal, Sebban, Catherine, Fischer, Thomas, Dührsen, Ulrich, Metzner, Bernd, Maschmeyer, Georg, Kanz, Lothar, Schmidt, Christian, Delarue, Richard, Brousse, Nicole, Klapper, Wolfram, Macintyre, Elizabeth, Delfau-Larue, Marie-Hélène, Pott, Christiane, Hiddemann, Wolfgang, Unterhalt, Michael, and Dreyling, Martin

Published
2016
Full Text
View/download PDF

5. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial

Author

Delarue, Richard, Tilly, Hervé, Mounier, Nicolas, Petrella, Tony, Salles, Gilles, Thieblemont, Catherine, Bologna, Serge, Ghesquières, Hervé, Hacini, Maya, Fruchart, Christophe, Ysebaert, Loïc, Fermé, Christophe, Casasnovas, Olivier, Van Hoof, Achiel, Thyss, Antoine, Delmer, Alain, Fitoussi, Olivier, Molina, Thierry Jo, Haioun, Corinne, and Bosly, André

Published
2013
Full Text
View/download PDF

6. High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network

Author

Hermine, Olivier, Jiang, Linmiao, Walewski, Jan, Bosly, André, Thieblemont, Catherine, Szymczyk, Michal, Pott, Christiane, Salles, Gilles, Feugier, Pierre, Hübel, Kai, Haioun, Corinne, Casasnovas, René Olivier, Schmidt, Christian, Bouabdallah, Kamal, Ribrag, Vincent, Kanz, Lothar, Dürig, Jan, Metzner, Bernd, Sibon, David, Cheminant, Morgane, Burroni, Barbara, Klapper, Wolfram, Hiddemann, Wolfgang, Unterhalt, Michael, Hoster, Eva, Dreyling, Martin, European Mantle Cell Lymphoma Network, UCL - SSS/IREC/MONT - Pôle Mont Godinne, and UCL - (MGD) Service d'hématologie

Subjects
Cancer Research, Oncology, Medizin
Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. In 2004, the European Mantle Cell Lymphoma (MCL) Network initiated the randomized open-label, phase III MCL Younger trial for first-line treatment of patients with advanced-stage MCL, age < 66 years, comparing an alternating rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone/rituximab plus dexamethasone, high-dose cytarabine, and cisplatin (R-CHOP/R-DHAP) induction followed by high-dose cytarabine-containing myeloablative radiochemotherapy conditioning and autologous peripheral blood stem-cell transplantation (R-DHAP arm) to R-CHOP with standard myeloablative radiochemotherapy and autologous stem-cell transplantation (R-CHOP arm). After a median follow-up of 10.6 years, the time to treatment failure was still significantly improved in the R-DHAP versus R-CHOP arms (medians 8.4 v 3.9 years, 5-/10-year rates 64%/46% v 41%/25%, P = .038, hazard ratio, 0.59). Median overall survival (OS) was not reached in the R-DHAP arm versus 11.3 years in R-CHOP arm (5-/10-year rates, 76%/60% v 69%/55%, P = .12). The unadjusted OS hazard ratios (0.80 [95% CI, 0.61 to 1.06], P = .12) reached significance when adjusted for Mantle Cell Lymphoma International Prognostic Index (MIPI) and MIPI + Ki-67 (MIPI-c) (0.74; 95% CI, 0.56 to 0.98; P = .038 and .60; 95% CI, 0.41 to 0.87; P = .0066). The incidence of secondary hematologic malignancies tended to be higher in the R-DHAP arm (4.5% v 1.4% at 10 years). With mature long-term data, we confirm the previously observed substantially prolonged time to treatment failure and, for the first time to our knowledge, show an improvement of OS. Some patients with MCL may be cured.

Published
2022

7. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

Author

Récher, Christian, Coiffier, Bertrand, Haioun, Corinne, Molina, Thierry Jo, Fermé, Christophe, Casasnovas, Olivier, Thiéblemont, Catherine, Bosly, André, Laurent, Guy, Morschhauser, Franck, Ghesquières, Hervé, Jardin, Fabrice, Bologna, Serge, Fruchart, Christophe, Corront, Bernadette, Gabarre, Jean, Bonnet, Christophe, Janvier, Maud, Canioni, Danielle, Jais, Jean-Philippe, Salles, Gilles, and Tilly, Hervé

Published
2011
Full Text
View/download PDF

8. 90Y Ibritumomab Tiuxetan (Zevalin) Combined With BEAM (Z -BEAM) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed or Refractory Low-grade CD20-positive B-cell Lymphoma. A GELA Phase II Prospective Study

Author

Decaudin, Didier, Mounier, Nicolas, Tilly, Hervé, Ribrag, Vincent, Ghesquières, Hervé, Bouabdallah, Krimo, Morschhauser, Franck, Coiffier, Bertrand, Le Gouill, Steven, Bologna, Serge, Delarue, Richard, Huynh, Anne, Bosly, André, Brière, Josette, and Gisselbrecht, Christian

Published
2011
Full Text
View/download PDF

9. High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network.

Author

Hermine, Olivier, Jiang, Linmiao, Walewski, Jan, Bosly, André, Thieblemont, Catherine, Szymczyk, Michal, Pott, Christiane, Salles, Gilles, Feugier, Pierre, Hübel, Kai, Haioun, Corinne, Casasnovas, René Olivier, Schmidt, Christian, Bouabdallah, Kamal, Ribrag, Vincent, Kanz, Lothar, Dürig, Jan, Metzner, Bernd, Sibon, David, and Cheminant, Morgane

Published
2023
Full Text
View/download PDF

10. CAR-T cells : new developments and implications in lymphoma

Author

Crochet, Gilles, Collinge, Elodie, Vellemans, Hélène, Bosly, André, André, Marc, UCL - SSS/IREC/MONT - Pôle Mont Godinne, and UCL - (MGD) Service d'hématologie

Subjects
relapsed/refractory B-cell lymphoma, Anti-CD19 CAR-T cells, cytokine release syndrome
Abstract

Recently, the use of chimeric antigen receptor modified T cells or CAR-T cells has emerged in the therapeutic arsenal of several hematological pathologies, including lymphoma. These CAR-T are the product of extensive research on understanding the mechanisms of tumour immunity and are the product of cellular engineering. By combining the specific recognition of an antibody and the activation pathways of a cytotoxic cell, CAR-T cells allow promising clinical results, but they also see the occurrence of side effects that are more specific to these traetments, which it is essential to manage in a multidisciplinary team. The trail that have enabled their use differ on many points, including patient selection, the manufacture of the CAR or the pre-therapeutic conditioning. In the future, the use of this expensive therapy could be extended to other lymphomas and new generations of CAR-T cells could emerge.

Published
2021

25. Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies

Author

Cabannes‐Hamy, Aurélie, Peyrade, Frederic, Jardin, Fabrice, Emile, Jean‐François, Delwail, Vincent, Mounier, Nicolas, Haioun, Corinne, Perrot, Aurore, Fitoussi, Olivier, Lara, Diane, Delarue, Richard, André, Marc, Offner, Fritz, Ghesquières, Hervé, Pascal, Laurent, Soussain, Carole, Lazarovici, Julien, Schiano, Jean-Marc, Gaulard, Philippe, Tilly, Hervé, Thieblemont, Catherine, LYSA (LYmphoma Study Association), Bosly, André, Van Den Neste, Eric, Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay, CIC - Poitiers, Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d’Oncologie Hématologique et Thérapie Cellulaire [CHU Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Gvh et Gvl : Physiopathologie Chez l'Homme et Chez l'Animal, Incidence et Role Therapeutique, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Polyclinique Bordeaux Nord Aquitaine, Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), Service d'immuno-hématologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Groupe de Recherche d'Histoire (GRHis), Normandie Université (NU)-Normandie Université (NU)-Institut de Recherche Interdisciplinaire Homme et Société (IRIHS), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Universiteit Gent = Ghent University [Belgium] (UGENT), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), CRLCC René Huguenin, Département d'hématologie [Gustave Roussy], Institut Gustave Roussy (IGR), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Laboratoire de Biologie Moléculaire de la Cellule (LBMC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Polyclinique Bordeaux Nord Aquitaine (PBNA), Universiteit Gent = Ghent University (UGENT), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Centre Antoine Lacassagne, CRLCC Antoine Lacassagne, Laboratoire épidémiologie et oncogénèse des tumeurs digestives, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Ghent University [Belgium] (UGENT), Université de Lille, CHU Lille, UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, and UCL - (SLuc) Service d'hématologie

Subjects
Male, Cancer Research, CHOP CHEMOTHERAPY, [SDV]Life Sciences [q-bio], Aggressive lymphoma, Central Nervous System Neoplasms, chemistry.chemical_compound, 0302 clinical medicine, Recurrence, Medicine and Health Sciences, SINGLE-ARM, Medicine, Cumulative incidence, ELDERLY-PATIENTS, ComputingMilieux_MISCELLANEOUS, Original Research, CNS relapse, Aged, 80 and over, education.field_of_study, Incidence (epidemiology), 3. Good health, CNS PROPHYLAXIS, Oncology, 030220 oncology & carcinogenesis, Female, Rituximab, Lymphoma, Large B-Cell, Diffuse, medicine.drug, medicine.medical_specialty, Population, PHASE-2 TRIAL, Ofatumumab, elderly, STUDY-GROUP DSHNHL, 03 medical and health sciences, Internal medicine, Humans, Radiology, Nuclear Medicine and imaging, NON-HODGKINS-LYMPHOMA, education, Aged, Retrospective Studies, AGGRESSIVE LYMPHOMA, business.industry, Clinical Cancer Research, Retrospective cohort study, medicine.disease, chemistry, Aged 80 and over, RITUXIMAB ERA, DLBCL, RISK-FACTORS, business, Diffuse large B-cell lymphoma, 030215 immunology
Abstract

CNS relapse is reported in 2–5% of diffuse large B‐cell lymphoma (DLBCL) patients, dramatically decreasing overall survival (OS). Very few studies address incidence and risk factors of CNS relapse in very elderly patients, a challenging population to treat given their commonly associated comorbidities. A retrospective analysis was performed of 270 DLBCL patients >80 years treated between 2004 and 2013 in two multicentre phase II LYSA trials (LNH03‐7B, LNH09‐7B) evaluating the addition of rituximab or ofatumumab to mini‐CHOP as front‐line therapy. No patients received CNS prophylaxis. CNS relapse was evaluated according to cumulative incidence, patient characteristics, risk factors, and survival. Median age was 83 years (range: 79–95). After a median follow‐up of 28.7 months, eight patients had CNS relapse (3.0%). Median time between inclusion and CNS relapse was 19.2 months (range: 3.2–32.6). Patients survived a median of 1.5 months after CNS relapse (range: 0.4–4.1). Median OS from relapse was significantly lower in CNS relapse patients (1.5 months, 95% CI: 0.4–3.5) compared to patients with non‐CNS relapse (6.6 months; 95% CI: 4.6–11.9). No baseline characteristics were associated with CNS relapse. The proportion of patients with CNS disease did not differ significantly between patients with low‐intermediate risk according to CNS‐IPI and patients with high risk (3% vs. 2.8%, P = 1.00). CNS relapse cumulative incidence in very elderly treatment‐naive patients is 1.8% at 2 years and is associated with poor survival. This population had a long median time to CNS relapse. Absence of prophylaxis did not strongly impact CNS relapse incidence.

Published
2018

26. The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma

Author

Machiels Jean-Pascal, Lalami Yassine, Henry Stéphanie, Focan Christian, Cocquyt Véronique, Bries Greet, Bosly André, Awada Ahmad, Lamotte Mark, Gerlier Laetitia, Mebis Jeroen, Straetmans Nicole, Verhoeven Didier, and Somers Luc

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background The use of chemotherapy regimens with moderate or high risk of febrile neutropenia (defined as having a FN incidence of 10% or more) and the respective incidence and clinical management of FN in breast cancer and NHL has not been studied in Belgium. The existence of a medical need for G-CSF primary and secondary prophylaxis with these regimens was investigated in a real-life setting. Methods Nine oncologists and six hematologists from different Belgian general hospitals and university centers were surveyed to collect expert opinion and real-life data (year 2007) on the use of chemotherapy regimens with moderate or high risk of febrile neutropenia and the clinical management of FN in patients aged Results The most frequently used regimens in breast cancer patients (n = 161) were FEC (45%), FEC-T (37%) and docetaxel alone (6%). In NHL patients (n = 39), R-CHOP-21 (33%) and R-ACVBP-14 (15%) were mainly used. Without G-CSF primary prophylaxis (PP), FN occurred in 31% of breast cancer patients, and 13% had PSN. After G-CSF secondary prophylaxis (SP), 4% experienced further FN events. Only 1 breast cancer patient received PP, and did not experience a severe neutropenic event. Overall, 30% of chemotherapy cycles observed in breast cancer patients were protected by PP/SP. In 10 NHL patients receiving PP, 2 (20%) developed FN, whereas 13 (45%) of the 29 patients without PP developed FN and 3 (10%) PSN. Overall, 55% of chemotherapy cycles observed in NHL patients were protected by PP/SP. Impaired chemotherapy delivery (timing and/or dose) was reported in 40% (breast cancer) and 38% (NHL) of patients developing FN. Based on oncologist expert opinion, hospitalization rates for FN (average length of stay) without and with PP were, respectively, 48% (4.2 days) and 19% (1.5 days). Similar rates were obtained from hematologists. Conclusions Despite the studied chemotherapy regimens being known to be associated with a moderate or high risk of FN, upfront G-CSF prophylaxis was rarely used. The observed incidence of severe neutropenic events without G-CSF prophylaxis was higher than generally reported in the literature. The impact on medical resources used is sizeable.

Published
2010
Full Text
View/download PDF

28. Carboplatin in association with etoposide and either adriamycin or epirubicin for untreated small cell lung cancer: A dose escalation study of carboplatin

Author

Humblet, Yves, Weynants, Patrick, Bosly, André, Majois, Françoise, Duprez, Pierre, Francis, Charles, Beauduin, Marc, Machiels, Jacques, Gailly, Charles, Delaunois, Luc, Rodenstein, Daniel, Doyen, Chantal, Longueville, Jacques, Michel, Claude, Schallier, Denis, Prignot, Jacques, Symann, Michel, and UCL Clinical Oncology Group

Published
1989
Full Text
View/download PDF

29. Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study

Author

Drach, Johannes, Bunworasate, Udomsak, Masliak, Zvenyslava, Vilchevskaya, Kateryna, Robak, Tadeusz, Pei, Lixia, Rooney, Brendan, van de Velde, Helgi, Cavalli, Franco, Huang, Huiqiang, Samoilova, Olga, Belch, Andrew, Farber, Charles, Bosly, André, Novak, Jan, Zaucha, Jan, and Dascalescu, Angela

Subjects
MANTLE cell lymphoma, BORTEZOMIB, RITUXIMAB, PREDNISONE, STEM cell transplantation
Abstract

This post-hoc subanalysis of the LYM-3002 phase 3 study assessed the efficacy and safety of substituting vincristine in rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHOP; n = 42) for bortezomib (VR-CAP; n = 38) in a subgroup of 80 mantle cell lymphoma (MCL) patients aged <60 years who did not receive stem cell transplantation (SCT) despite medical eligibility. Complete response (CR)/unconfirmed CR (CRu) rates were 67 vs. 39% (odds ratio 3.69 [95% CI(confidence interval): 1.31, 10.41]; p = .012). After 40 months median follow-up, median progression-free survival by independent radiology committee with VR-CAP vs. R-CHOP was 32.6 vs. 12.0 months (hazard ratio (HR) 0.59 [95% CI: 0.31, 1.13]; p = .108); median overall survival was not reached vs. 47.3 months (HR 0.81 [95% CI: 0.33, 1.96]; p = .634). Adverse events included neutropenia (92/76%), thrombocytopenia (70/10%) and leukopenia (65/50%). VR-CAP represents a potential alternative to R-CHOP in combined and/or alternating regimens for younger, SCT-eligible MCL patients. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

31. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.

Author

Zucca, Emanuele, Conconi, Annarita, Martinelli, Giovanni, Bouabdallah, Reda, Tucci, Alessandra, Vitolo, Umberto, Martelli, Maurizio, Pettengell, Ruth, Salles, Gilles, Sebban, Catherine, Guillermo, Armando Lopez, Pinotti, Graziella, Devizzi, Liliana, Morschhauser, Franck, Tilly, Hervé, Torri, Valter, Hohaus, Stefan, Ferreri, Andrés J. M., Zachée, Pierre, and Bosly, André

Published
2017
Full Text
View/download PDF

32. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial

Author

Dombret, Hervé, Gabert, Jean, Boiron, Jean-Michel, Rigal-Huguet, Françoise, Blaise, Didier, Thomas, Xavier, Delannoy, André, Buzyn, Agnès, Bilhou-Nabera, Chrystèle, Cayuela, Jean-Michel, Fenaux, Pierre, Bourhis, Jean-Henri, Fegueux, Nathalie, Charrin, Christiane, Boucheix, Claude, Lhéritier, Véronique, Espérou, Hélène, MacIntyre, Elizabeth, Vernant, Jean-Paul, Fière, Denis, Groupe d'Etude et de Traitement de la Leucémie Aiguë Lymphoblastique de l'Adulte (GET-LALA Group), André, Marc, Bosly, André, Chatelain, Bernard, MINEUR, Géraldine, Sonet, Anne, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Laboratoire de biologie clinique, and UCL - (MGD) Service d'hématologie

Subjects
Adult, Male, medicine.medical_specialty, Neoplasm, Residual, Time Factors, Adolescent, Immunology, Fusion Proteins, bcr-abl, Biochemistry, Gastroenterology, hemic and lymphatic diseases, Internal medicine, Acute lymphocytic leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Survival analysis, Mitoxantrone, Hematology, Ploidies, business.industry, Reverse Transcriptase Polymerase Chain Reaction, Patient Selection, Remission Induction, Cytarabine, Cell Biology, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, medicine.disease, Prognosis, Minimal residual disease, Survival Analysis, Surgery, Transplantation, Leukemia, Treatment Outcome, Female, business, medicine.drug, Follow-Up Studies, Stem Cell Transplantation
Abstract

From 1994 to 2000, 154 adults with Philadelphia chromosome-positive (Ph+) and/or BCR-ABL(+) acute lymphoblastic leukemia (ALL) were treated according to a prospective trial (median follow-up, 4.5 years) with the aim to study the prognostic value of early response to therapy and the role of stem cell transplantation (SCT) in first complete remission (CR). All patients received a standard induction course followed by a course of mitoxantrone and intermediate-dose cytarabine (HAM). After each course, minimal residual disease was tested by specific reverse transcriptase-polymerase chain reaction (RT-PCR) (median sensitivity, 10(-5)). Allogeneic SCT (if a donor) or autologous SCT (if not) was planned at 3 months in all patients in CR after HAM. CR rates after induction, after HAM, and at 3 months were 53%, 67%, and 62%, respectively. High leukocyte count and m-bcr subtype were the 2 identified bad-prognosis factors for CR at 3 months, both superseded by a poor early response assessed at day 8 of the induction course. HAM-associated salvage rate was higher in patients with M-bcr than in those with m-bcr ALL (55% vs 30%; P = .05). In the 103 patients eligible for SCT, the existence of a donor and the negative BCR-ABL status after HAM were independently predictive of remission duration (P < .001 and .01, respectively) and survival (P = .02 and .01, respectively). Relapse was the most common cause of treatment failure in all patient groups. Allogeneic SCT in first CR is the current best treatment option in adults with the disease. New strategies must be tested during early phases of therapy to increase the rate of BCR-ABL(-) remissions. (C) 2002 by The American Society of Hematology.

Published
2002

33. Integrative Analysis of Diffuse Large B Cell Lymphoma Mutational Landscape: A Lysa Study

Author

Dubois, Sydney, Tesson, Bruno, Viailly, Pierre-Julien, Molina, Thierry, Copie-Bergman, Christiane, Mareschal, Sylvain, Bohers, Elodie, Bertrand, Philippe, Ruminy, Philippe, Maingonnat, Catherine, Jais, Jean-Philippe, Peyrouze, Pauline, Figeac, Martin, Desmots, Fabienne, Fest, Thierry, Haioun, Corinne, Lamy, Thierry, Briere, Josette, Petrella, Tony, Canioni, Danielle, Fabiani, Bettina, Coiffier, Bertrand, Delarue, Richard, Peyrade, Frederic, Bosly, André, Andre, Marc, Ketterer, Nicolas, Salles, Gilles A., Tilly, Hervé, Leroy, Karen, and Jardin, Fabrice

Published
2015
Full Text
View/download PDF

34. Efficacy and Safety of Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in a Subset of Newly Diagnosed Mantle Cell Lymphoma (MCL) Patients (Pts) Medically Eligible for Transplantation in the Randomized Phase 3 LYM-3002 Study (NCT00722137)

Author

Drach, Johannes, Huang, Huiqiang, Samoilova, Olga S, Belch, Andrew, Farber, Charles M., Bosly, André, Novak, Jan, Zaucha, Jan, Dascalescu, Angela, Bunworasate, Udomsak, Masliak, Zvenyslava, Vilchevskaya, Kateryna, Robak, Tadeusz, Pei, Lixia, Rooney, Brendan, van de Velde, Helgi, and Cavalli, Franco

Published
2014
Full Text
View/download PDF

35. Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma.

Author

Nols, Nathalie, Mounier, Nicolas, Bouazza, Salima, Lhommel, Renaud, Costantini, Sabrina, Vander Borght, Thierry, Vekemans, Marie-Christiane, Sonet, Anne, Bosly, André, Michaux, Lucienne, André, Marc, and Van Den Neste, Eric

Subjects
B cell lymphoma, B cells, PROGNOSIS, HEALTH outcome assessment, POSITRON emission tomography, LYMPHOMAS
Abstract

The prognostic value of interim 18fluorodeoxyglucose positron emission tomography (i-PET) was investigated in 73 patients (median age 60 years) with diffuse large B-cell lymphoma (DLBCL). i-PET was analyzed using the Deauville score (DS) and change in maximum standardized uptake value (ΔSUVmax). Patients with a DS of 1-3 demonstrated a significantly ( p < 0.0001) better outcome (median follow-up 2.4 years) than patients with a score of 4 or 5 in terms of event-free survival (EFS) (79% vs. 36%), progression-free survival (PFS) (84% vs. 47%) and overall survival (OS) (91% vs. 51%). EFS (73% vs. 42%), PFS (78% vs. 50%) and OS (88% vs. 56%) were also significantly ( p = 0.023) different between patients with ΔSUVmax > 66% or ≤ 66%. Patients ( n = 33) combining a favorable age-adjusted International Prognostic Index (IPI) (0 or 1) and a negative i-PET either by DS or ΔSUVmax criteria showed a particularly good outcome (EFS: 85%, PFS: 88%, OS: 94%). Overall, i-PET was highly and independently predictive of any outcome, and its negative predictive value was improved by combination with IPI. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

39. Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma.

Author

Jardin, Fabrice, Delfau-Larue, Marie Hélène, Molina, Thierry Jo, Copie-Bergman, Christiane, Brière, Josette, Petrella, Tony, Canioni, Danielle, Fabiani, Bettina, Jais, Jean-Philippe, Figeac, Martin, Leroy, Karen, Mareschal, Sylvain, Salles, Gilles André, Coiffier, Bertrand, Delarue, Richard, Peyrade, Frédéric, Bosly, André, André, Marc, Ketterer, Nicolas, and Haioun, Corinne

Subjects
HEALTH outcome assessment, B cell lymphoma, LYMPHOMAS, GENE expression, IMMUNOHISTOCHEMISTRY, IMMUNOGLOBULINS
Abstract

Elevated serum free light chains (FLCs) have been associated with an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL). The aim of this study was to determine the clinical relevance of a quantitative assessment of intact circulating immunoglobulin (Ig), using serum Ig heavy chain/light chain pair (HLC) measurements in patients with DLBCL. FLC and HLC were measured in 409 serum samples of patients with DLBCL included in the LNH03-B clinical trial program of the Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Patients with an abnormal IgMκ/IgMλ ratio or an abnormal FLC ratio more frequently displayed adverse clinical characteristics. Patients with abnormal IgMκ/IgMλ ratios had inferior progression-free survival (PFS) and overall survival (OS) as compared to patients with a normal ratio in the overall cohort (5-year PFS 44.9% vs. 69.3%, p = 0.0003 and 5-year OS 50.8% vs. 78.1%, p = 0.0003) and in the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) cohort (5-year OS 43.5% vs. 70.3%, p = 0.003). In multivariate analysis, including elevated FLC/HLC and International Prognostic Index (IPI), an abnormal IgMκ/IgMλ ratio (hazard ratio [HR] = 1.54, 95% confidence interval [CI] 1.03-2.3, p = 0.03) remained predictive of shorter progression-free survival. Gene expression profile experiments and immunohistochemistry indicate that this measurement is at least partially related to tumor cell secretion. Both elevated serum FLCs and an abnormal IgMκ/IgMλ ratio are associated with unfavorable outcomes in patients with DLBCL treated by R-CHOP. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

40. Integrated Analysis of High-Resolution Gene Expression and Copy Number Profiling Identified Biallelic Deletion of CDKN2A/2B Tumor Suppressor Locus As the Most Frequent and Unique Genomic Abnormality in Diffuse Large B-Cell Lymphoma (DLBCL) with Strong Prognostic Value in Both GCB and ABC Subtypes and Not Overcome by a Dose-Intensive Immunochemotherapy Regimen Plus Rituximab. Results of a Prospective GELA Clinical Trial Program

Author

Jardin, Fabrice, Mareschal, Sylvain, Figeac, Martin, Jais, Jean-Philippe, Leroy, Karen, Copie-Bergman, Christiane, Salles, Gilles Andre, Coiffier, Bertrand, Delarue, Richard, Peyrade, Frederic, Bosly, Andre, Ketterer, Nicolas, Haioun, Corinne, Tilly, Herve, and Molina, Thierry Jo

Published
2012
Full Text
View/download PDF

41. Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final Analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net)

Author

Hermine, Olivier, Hoster, Eva, Walewski, Jan, Ribrag, Vincent, Brousse, Nicole, Thieblemont, Catherine, Bouabdallah, Reda, Dohner, Hartmut, Feugier, Pierre, Forspointner, Roswitha, Haioun, Corinne, Kneba, Michael, Hänel, Mathias, Casasnovas, Olivier, Mertelsmann, Roland H., Hallek, Michael, Bosly, Andre, Nowacki, M, Klapper, Wolfram, Gisselbrecht, Christian, Coiffier, Bertrand, Unterhalt, Michael, Hiddemann, Wolfgang, and Dreyling, Martin H.

Published
2012
Full Text
View/download PDF

42. The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin¿s lymphoma.

Author

Gerlier, Laetitia, Lamotte, Mark, Awada, Ahmad, Bosly, André, Bries, Greet, Cocquyt, Véronique, Focan, Christian, Henry, Stéphanie, Lalami, Yassine, Machiels, Jean-Pascal, Mebis, Jeroen, Straetmans, Nicole, Verhoeven, Didier, and Somers, Luc

Subjects
FEBRILE neutropenia, CANCER chemotherapy, BREAST cancer, LYMPHOMAS, CANCER patients
Abstract

Background: The use of chemotherapy regimens with moderate or high risk of febrile neutropenia (defined as having a FN incidence of 10% or more) and the respective incidence and clinical management of FN in breast cancer and NHL has not been studied in Belgium. The existence of a medical need for G-CSF primary and secondary prophylaxis with these regimens was investigated in a real-life setting. Methods: Nine oncologists and six hematologists from different Belgian general hospitals and university centers were surveyed to collect expert opinion and real-life data (year 2007) on the use of chemotherapy regimens with moderate or high risk of febrile neutropenia and the clinical management of FN in patients aged <65 years with breast cancer or NHL. Data were retrospectively obtained, over a 6-month observation period. Results: The most frequently used regimens in breast cancer patients (n = 161) were FEC (45%), FEC-T (37%) and docetaxel alone (6%). In NHL patients (n = 39), R-CHOP-21 (33%) and R-ACVBP-14 (15%) were mainly used. Without G-CSF primary prophylaxis (PP), FN occurred in 31% of breast cancer patients, and 13% had PSN. After G-CSF secondary prophylaxis (SP), 4% experienced further FN events. Only 1 breast cancer patient received PP, and did not experience a severe neutropenic event. Overall, 30% of chemotherapy cycles observed in breast cancer patients were protected by PP/SP. In 10 NHL patients receiving PP, 2 (20%) developed FN, whereas 13 (45%) of the 29 patients without PP developed FN and 3 (10%) PSN. Overall, 55% of chemotherapy cycles observed in NHL patients were protected by PP/SP. Impaired chemotherapy delivery (timing and/or dose) was reported in 40% (breast cancer) and 38% (NHL) of patients developing FN. Based on oncologist expert opinion, hospitalization rates for FN (average length of stay) without and with PP were, respectively, 48% (4.2 days) and 19% (1.5 days). Similar rates were obtained from hematologists. Conclusions: Despite the studied chemotherapy regimens being known to be associated with a moderate or high risk of FN, upfront G-CSF prophylaxis was rarely used. The observed incidence of severe neutropenic events without G-CSF prophylaxis was higher than generally reported in the literature. The impact on medical resources used is sizeable. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

44. Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma.

Author

Bosly, André, Lepage, Eric, Coiffier, Bertrand, Fillet, Georges, Herbrecht, Raoul, Divine, Marine, Dupriez, Brigitte, Nouvel, Christiane, Deconninck, Eric, Tilly, Hervé, Bordessoule, Dominique, Gaulard, Philippe, and Gisselbrecht, Christian

Subjects
*DRUG therapy, *LYMPHOMA treatment
Abstract

Introduction: A prospective randomised study involving 810 elderly patients was conducted in an attempt to compare alternating chemotherapy with conventional first-line chemotherapy in aggressive non-Hodgkin’s lymphoma in order to improve prognosis with an acceptable toxicity for elderly patients.Patients and methods: Patients included were 55–69 years old and had at least one adverse prognostic factor. Patients were treated either with ACVBP followed by consolidation (n = 396) or with an alternating regimen (n = 414). This regimen was an association of active drugs in NHL relapsing patients, alternating VIMMM with ACVBP for induction and alternation of VIM and ACVM in consolidation. Eight hundred and sixty-six patients were randomised. After histological review, 810 patients met the inclusion criteria: 396 in arm A, 414 in arm B.Results: The complete response rate after induction was superior for conventional first-line therapy (58.5% vs 48%, P = 0.003) but at the end of treatment, the CR rate was not statistically different (52% vs 48%, P = 0.19). Conventional chemotherapy had a better five-year event-free survival than alternating regimen (33% (95% CI: 30–36%) vs 28% (95% CI: 26–30%), P = 0.0289) but overall survival was not statistically different (40% (CI 95% 38–42%) vs 36% (CI 95% 34–38%), P = 0.068). In this elderly high risk population, the toxicity was very high: 19% in arm A and 26% in arm B died during treatment.Conclusion: Alternating regimen did not improve outcome, was less efficient and more toxic.The Hematology Journal (2001) 2, 279–285 [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

45. Prognostic Role of Host Immune Gene Polymorphisms for Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab and Chemotherapy. A Study Based on 554 Patients Included in the GELA (Groupe d'Etude des Lymphomes de l'Adulte) Prospective Multicentric Program LNH2003,

Author

Ghesquieres, Herve, Jardin, Fabrice, Pallardy, Sophie, Verney, Aurélie, Borrel, Anne Laure, Ketterer, Nicolas, Recher, Christian, Delarue, Richard, Bosly, Andre, Coiffier, Bertrand, Casasnovas, Rene-Olivier, Fitoussi, Olivier, Peyrade, Frederic, Ribrag, Vincent, Zelenika, Diana, Tilly, Herve, Haioun, Corinne, and Salles, Gilles Andre

Published
2011
Full Text
View/download PDF

46. FCGR3A and FCGR2A Polymorphisms Do Not Affect Response and Outcome of Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab and Chemotherapy. A Study Based on 554 Patients Included in GELA (Groupe d'Etude des Lymphomes de l'Adulte) Prospective Multicentric Study LNH2003

Author

Ghesquieres, Herve, Jardin, Fabrice, Pallardy, Sophie, Verney, Aurélie, Borrel, Anne Laure, Ketterer, Nicolas, Recher, Christian, Delarue, Richard, Bosly, Andre, Coiffier, Bertrand, Casasnovas, Rene-Olivier, Fitoussi, Olivier, Peyrade, Frederic, Ribrag, Vincent, Zelenika, Diana, Tilly, Herve, Haioun, Corinne, and Salles, Gilles Andre

Published
2011
Full Text
View/download PDF

48. Complete Response After High-Dose Methotrexate-Based Chemotherapy as a Major Prognostic Factor for Primary CNS Lymphoma: An Exploratory Analysis of the LNHCP93 Trial of the Groupe d'Etude Des Lymphomes De l'Adulte.

Author

Ghesquières, Hervé, Ferlay, Celine, Bajard, Agathe, Sebban, Catherine, Perol, David, Bosly, Andre, Casasnovas, Olivier, Reman, Oumedaly, Coiffier, Bertrand, Tilly, Herve, Morel, Pierre, De Prijck, Bernard, Van Den Neste, Eric, Colin, Philippe, Ketterer, Nicolas, Antoine, Thyss, Delannoy, Andre, Haioun, Corinne, Devidas, Alain, Biron, Pierre, and Blay, Jean-Yves

Published
2009
Full Text
View/download PDF

49. Interim Analysis of the IELSG-19 Randomised Study of Chlorambucil Alone Versus Chlorambucil Plus Rituximab Versus Rituximab Alone in Extranodal Marginal Zone Lymphomas of Mucosa-Associated Lymphoid Tissue (MALT lymphoma).

Author

Zucca, Emanuele, Conconi, Annarita, Martelli, Maurizio, Thieblemont, Catherine, Johnson, Peter, Guillermo, Armando Lopez, Bouabdallah, Reda, Tucci, Alessandra, Vitolo, Umberto, Coiffier, Bertrand, Devizzi, Liliana, Jardin, Fabrice, Sebban, Catherine, Pinotti, Graziella, Morschhauser, Franck, Pettengell, Ruth, Bosly, André, Montserrat, Emilio, Bellei, Monica, Pileri, Stefano A., Copie-Bergman, Christiane, Campo, Elias, Jack, Andrew, Mazzucchelli, Luca, Floriani, Irene, Garavaglia, Daniela, Torri, Valter, Cavalli, Franco, and Martinelli, Giovanni

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results